Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Cholinergic Urticaria
NCT02012387Phase 2Completed
- Sponsor
- Universidad de Navarra
- Start
- Jan 2014
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in Cholinergic Urticaria (CU), sponsored by Universidad de Navarra. Started Jan 2014; status: completed.
02
Drugs
omalizumab
03
Conditions
Cholinergic Urticaria (CU)
Beyond the preview
Go deeper on NCT02012387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02012387.